Last updated on August 2019

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)


Brief description of study

The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression.

Clinical Study Identifier: NCT03631706

Find a site near you

Start Over

UC Irvine Medical Center

Orange, CA United States
  Connect »

UZ Leuven

Pellenberg, Belgium
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Sansum Clinic - Santa Barbara

Santa Barbara, CA United States
  Connect »

Woodlands Medical Specialists

Pensacola, FL United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

UPMC Cancer Center

Pittsburgh, PA United States
  Connect »

SCRI - Tennessee Oncology

Nashville, TN United States
  Connect »

Texas Oncology - Bedford

Bedford, TX United States
  Connect »

Centro Medico San Roque S.R.L.

San Miguel de Tucuman, Argentina
  Connect »

Sharp Memorial Hospital (6993)

San Diego, CA United States
  Connect »

Instituto Medico Especializado Alexander Fleming

Ciudad Autonoma Buenos Aires, Argentina
  Connect »